• Global DAYBUE net sales projected to reach ~US$700m in 2028
• DAYBUE STIX formulation US launch commencing in Q1 2026
• DAYBUE oral solution approved by Ministry of Health in Israel
• Top-line data from Phase 3 trial of trofinetide in Japan expected Q4 2026 / Q1 2027

Neuren Pharmaceuticals (ASX: NEU) today reported highlights from the presentation and discussion by its partner Acadia Pharmaceuticals (Nasdaq: ACAD) at the 44th annual J.P. Morgan Healthcare Conference. Acadia projected DAYBUE global net sales to reach ~US$700m in 2028, with growth driven by the rollout of the DAYBUE STIX (approved by US FDA in December 2025) that could potentially enable patient growth from families who had declined to try or discontinued the liquid formulation, continued benefits from the Q2 2025 expansion of US customer-facing teams, and international expansion, assuming approval in Europe (CHMP opinion anticipated Q1 2026). Since DAYBUE's launch in the US in 2023, more than 2,000 Rett syndrome patients have been treated by DAYBUE, and persistency at 12 months has now increased to 55%. Outside the US, Acadia announced the approval of DAYBUE oral solution by the Ministry of Health in Israel. The Phase 3 clinical trial of trofinetide in Japan is ongoing with top-line results expected between Q4 2026 and Q1 2027.

Global DAYBUE net sales projected to reach ~US$700m in 2028